17 March 2004

GENESIS Pharma S.A., one of the fastest growing pharmaceutical companies in Greece, with vast experience in marketing, selling and distributing niche pharmaceutical products for chronic and rare diseases, has chosen CIVITAS for the design and implementation of a series of communicational projects, within the frame of corporate communication and public relations program.

The main target of this program is to strengthen GENESIS Pharma's image both domestically and internationally, by focusing on the Press, Media Training and Corporate Social Responsibility actions.

GENESIS Pharma was incorporated in 1997, with the vision to substantially contribute to the treatment of life- threatening diseases. The company focuses on marketing, sales and distribution of specialised products emerging from biotechnology research for rare and chronic diseases. In reinforcing its role in the market, GENESIS Pharma has accomplished strategic alliances with top biopharmaceutical companies and has developed a strong regional presence in Greece and Southeast Europe. Today, it represents top American and European companies of cellular and molecular technology such as Amgen, Biogen Idec, Chiron, Cephalon and Shire.

Mr. Costas Evripides, Genesis Pharma's CEO stated: "The criteria based on which we have chosen Civitas are its high standards of professional approach to communication, the variety of services it offers, along with its experienced and skilled personnel. We are confident that our collaboration with Civitas will assist us in achieving GENESIS Pharma's communicational goals in a particularly competitive market".

Mr. Dave Robinson, Executive Vice President of Civitas, commented: "GENESIS Pharma is a very significant client for Civitas. Pharmaceutical biotechnology is one of the fastest growing scientific and business sectors in the international market. Especially in Greece, we have noted a new era of development and maturation. Towards this direction and for the accomplishment of targets for the coming years, the right communicational strategy and implementation plays a significant role. I am confident that our collaboration with GENESIS Pharma will be successful and mutually constructive".